Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Elite Feature: Find Similar Charts in Seconds

GH Research PLC

Contributing Author

Recent Articles by GH Research PLC

Aug-06	GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update GHRS +5.18% GlobeNewswire
Jun-04	GH Research Announces Publication of Phase 2a Postpartum Depression Results GHRS GlobeNewswire
May-14	GH Research Reports First Quarter 2026 Financial Results and Provides Business Update GHRS GlobeNewswire
Apr-29	GH Research Announces Pricing of $117.5 Million Underwritten Offering GHRS GlobeNewswire
Apr-20	GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness GHRS +17.23% GlobeNewswire
Mar-25	GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD GHRS GlobeNewswire
Mar-05	GH Research Reports Full Year 2025 Financial Results and Provides Business Update GHRS -5.13% GlobeNewswire
Jan-05	GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 GHRS +16.77% GlobeNewswire
Jan-02	GH Research to Announce IND Status for GH001 GHRS GlobeNewswire
Nov-06	GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates GHRS GlobeNewswire
Oct-09	GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress GHRS GlobeNewswire
Aug-07	GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates GHRS GlobeNewswire
Jul-23	GH Research Announces Global Pivotal Program Plans and Further Development Updates GHRS -14.68% GlobeNewswire
Jun-20	GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule GHRS GHRS -5.12% GlobeNewswire
May-15	GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting GHRS +7.21% GlobeNewswire
May-08	GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates GHRS +5.16% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)